Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lung Neoplasms 10Burkitt Lymphoma 9Leukemia, Myeloid, Acute 8Lymphoma 7Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Sarcoma, Ewing 3Sarcoma 3Rhabdomyosarcoma 3Rhabdoid Tumor 3Retinoblastoma 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroblastoma 3Neoplasms, Germ Cell and Embryonal 3Myelodysplastic Syndromes 3Medulloblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia 3Immunoblastic Lymphadenopathy 3Seminoma 2

Interventions

Paclitaxel 2Topotecan 1Platinum 1Etoposide 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × SCLC × Etoposide × Clear all
NCT05844150 2025-03-12

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Biotheus Inc.

Phase 2 Active not recruiting
50 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡